Dian Diagnostics Group Co., Ltd. signed an agreement to acquire 51% stake in Qingdao Zhiying Medical Technology Co., Ltd. from Hangzhou Hailu Equity Investment Partnership Enterprise (Limited Partnership) for approximately CNY 580 million.
April 09, 2018
Share
Dian Diagnostics Group Co., Ltd. (SZSE:300244) signed an agreement to acquire 51% stake in Qingdao Zhiying Medical Technology Co., Ltd. from Hangzhou Hailu Equity Investment Partnership Enterprise (Limited Partnership) for approximately CNY 580 million on April 10, 2018. Dian Diagnostics Group Co., Ltd. will self-financed funds to acquire the stake in cash. Prior to the transaction, Hangzhou Hailu Equity Investment Partnership Enterprise (Limited Partnership) held 60% stake in Qingdao Zhiying Medical Technology Co., Ltd. After the transaction, Dian Diagnostics Group Co., Ltd. will hold 51% stake in Qingdao Zhiying Medical Technology Co., Ltd. Qingdao Zhiying Medical Technology Co., Ltd. reported total assets of CNY 749.07 million and total equity of CNY 493.5 million as at December 31, 2017. Qingdao Zhiying Medical Technology Co., Ltd. reported revenues of CNY 912.75 million, operating profit of CNY 149.84 million and net profit of CNY 111.98 million during the year ending December 31, 2017. The transaction is subject to approval of shareholders of Dian Diagnostics Group Co., Ltd. The Board of Directors of Dian Diagnostics Group Co., Ltd. approved the transaction on April 10, 2018.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Dian Diagnostics Group Co., Ltd. signed an agreement to acquire 51% stake in Qingdao Zhiying Medical Technology Co., Ltd. from Hangzhou Hailu Equity Investment Partnership Enterprise (Limited Partnership) for approximately CNY 580 million.
DIAN DIAGNOSTICS GROUP CO.,LTD. 
